Skip to main content
Psychopharmacology Bulletin › All Volumes & Issues › VOL 39 No. 1
PSYCHOPHARMACOLOGY BULLETIN

VOL 39 No. 1

Articles in This Issue

ORIGINAL RESEARCH

Suicide Risk Analysis Among Patients Assigned to Psychotropics and Placebo

Arif Khan, MD, Russell L. Kolts, PhD, Amy E. Brodhead, MS, K. Ranga Krishnan, MD, and Walter A. Brown, MD
Based on available data, it is unclear if the suicide risk is significantly different among clinical trial patients assigned to psychotropics compared with patients assigned to placebo, among patients with various psychiatric diagnoses. This study...
Pages 6-14 Read Article
ORIGINAL RESEARCH

A Randomized Controlled Trial of Paroxetine for Noncardiac Chest Pain

P. Murali Doraiswamy, MD, Indira Varia, MD, Caroline Hellegers, MA, H. Ryan Wagner, PhD, Greg L. Clary, MD, John L. Beyer, MD, L. Kristin Newby, MD, John F. O’Connor, MD, Katherine L. Beebe, PhD, Christopher O’Connor, MD, and K. Ranga R. Krishnan, MD
Noncardiac chest pain occurs frequently in medical practice and is often difficult to treat. We conducted a randomized double-blind, placebo-controlled, 8-week trial of paroxetine in 50 patients with noncardiac chest pain. None of the patients...
Pages 15-24 Read Article
ORIGINAL RESEARCH

Reliability and Validity of the Yale-Brown Obsessive-Compulsive Scale in Schizophrenia Patients

Lieuwe de Haan, MD, PhD, Britt Hoogeboom, MD, Nico Beuk, MD, Luuk Wouters, Peter M.A.J. Dingemans, PhD, and Don H. Linszen, MD, PhD
Although a sizeable minority of people with schizophrenia manifest obsessive and compulsive symptoms, to our knowledge there are no studies of the psychometric performance of measures such as the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS). The present...
Pages 25-30 Read Article
ORIGINAL RESEARCH

Brief Report: Paroxetine in Younger and Adult Individuals at High Risk for Suicide

Mark S. Bauer, MD, Stephen R. Wisniewski, PhD, Jane N. Kogan, PhD, Lauren B. Marangell, MD, Michael E. Thase, MD, Gary Sachs, MD, for the STEP-BD Investigators
Paroxetine has been associated with increased rates of suicidality in adolescents treated in antidepressant clinical trials. Regulatory agencies in the United States and the UK have issued warnings that are already changing clinical practice for...
Pages 31-37 Read Article
EVIDENCE-BASED MEDICINE

Rational Antidepressant Selection: Applying Evidence-Based Medicine to Complex Real-World Patients

Mark S. Bauer, MD, Stephen R. Wisniewski, PhD, Jane N. Kogan, PhD, Lauren B. Marangell, MD, Michael E. Thase, MD, Gary Sachs, MD, for the STEP-BD Investigators
Every clinician faces the daily question of which antidepressant is best for a particular depressed patient. Double-blind studies submitted for U.S. Federal Drug Administration marketing approval include only the “purest” population of patients, and the...
Pages 38-104 Read Article
DRUG DISPOSITION AND PHARMACOKINETICS

Efficacy of Olanzapine and Risperidone in Schizophrenia: A Randomized Double-Blind Crossover Design

Jose M. Canive, MD, Gregory A. Miller, PhD, Jessica G. Irwin, BS, Sandra N. Moses, PhD, Robert J. Thoma, PhD, J. Christopher Edgar, PhD, Andrea Sherwood, PhD, Fernando Torres, MD, Marianna LaNoue, PhD, Stephen Lewis, MD, Faith M. Hanlon, PhD, Michael P. Weisend, PhD, Valerie Mead, MD, and Vicente B. Tuason, MD
This article compares the efficacy of olanzapine and risperidone for positive and negative symptoms using an 18-week, randomized, double-blind, crossover design. The hypotheses were that olanzapine would be more efficacious for treating negative symptoms, and...
Pages 105-116 Read Article
COMPLICATED CASE HISTORIES

Priapism and Quetiapine: A Case Report

George Harrison, MD, James W. Dilley, MD, Lisa Loeb, MPH, and Kimberly Nelson
Priapism is a “persistent erection not accompanied by sexual desire or stimulation, usually lasting more than six hours and typically involving only the corpora cavernosa.” Here we report on a gay male patient from our...
Pages 117-119 Read Article